Published
17 minute read
By Dr. Michael Brandt, MD, MSc, EMBA, FRCSC, Otolaryngology Head and Neck Surgeon, FORM Face + Body, Toronto
Oral minoxidil has been getting a lot of attention lately. It seems to be everywhere—in hair-loss discussions, social media posts and conversations about treatments that don't involve surgery.
What's old is new again.
Minoxidil wasn't originally developed to grow hair. It was introduced decades ago as a medication for severe high blood pressure. Doctors noticed an unexpected side effect: patients were growing more hair. That observation eventually led to topical minoxidil, which many people now recognize by the brand name Rogaine.
Today, low-dose oral minoxidil is attracting renewed interest as a treatment for hair loss. Instead of applying a foam or solution to the scalp every day, some patients can take a prescription tablet.
It sounds easier. And for many patients, that's exactly the point.
I've had conversations with patients who started topical minoxidil with the best intentions, only to abandon it months later. Some dislike how it makes their hair feel. Others don't want to work a liquid or foam into their scalp every day, wait for it to dry, and then try to style their hair around it. Frankly, it becomes a pain, and they stop using it.
That may be the most compelling reason to consider oral minoxidil: not because the tablet necessarily grows more hair, but because patients may be more likely to take it consistently. Hair treatments only work when people actually use them.
The best comparative studies have not shown oral minoxidil to be consistently more effective than topical minoxidil. The real decision often comes down to adherence, convenience, tolerance, medical history and side effects.
Hair follicles cycle through periods of growth, transition and rest. In pattern hair loss, susceptible follicles gradually produce thinner, shorter hairs until some become barely visible.
Minoxidil can help follicles remain in the growing phase longer and can improve the size and appearance of some miniaturized hairs. Its full effect on the follicle is still being studied, and describing it simply as "improving scalp circulation" doesn't capture the whole story.
Importantly, minoxidil is not a DHT blocker. It does not correct the underlying hormonal susceptibility responsible for androgenetic alopecia, also called male- or female-pattern hair loss.
That is why minoxidil may be one component of a broader treatment plan rather than the only treatment someone needs.
Topical minoxidil is available in solutions and foams and has decades of clinical use behind it. It is a familiar first-line option for many men and women with pattern hair loss.
Its biggest advantage is that the medication is applied directly to the scalp, limiting systemic exposure compared with a tablet. Many patients tolerate it well, and it can improve hair density when used consistently over time.
The challenge is the routine—and the way the product can make the hair look and feel.
Some topical formulations leave a greasy, sticky or stiff residue. Hair may feel coated, clump together or become harder to style. This is particularly frustrating for patients who already feel self-conscious about thinning hair. It can also be inconvenient for people with long, thick or textured hair who need to part their hair carefully to get the medication onto the scalp rather than the strands.
The issue is often the formulation sitting on the hair, rather than a permanent change to the structure of the hair shaft. Foams and solutions can behave differently, so switching formulations may help some patients.
Others develop itching, flaking or contact dermatitis. Sometimes the irritation comes from ingredients such as propylene glycol rather than minoxidil itself.
But even without irritation, applying minoxidil every day can become tiresome. Patients travel, exercise, wash and style their hair, or simply forget. Then a few missed applications turn into weeks of inconsistent use, and eventually the bottle sits untouched.
A treatment that works in a clinical trial won't deliver its expected benefit if someone finds it too inconvenient to use consistently.
This isn't just an observation from clinical practice. There's published research behind it.
In a small 2025 survey comparing oral and topical minoxidil, patients taking oral medication reported that treatment was easier and that styling their hair was less difficult. Topical users missed more treatment days on average. Approximately 19% of the topical group said they had stopped treatment because it was difficult to use, compared with none of the oral group.
The study included only 50 patients and was observational, so it cannot prove that switching to a tablet will improve adherence in everyone. But it captures a common practical problem.
Other studies have found that patients frequently discontinue topical minoxidil before giving it enough time to work. A 2023 adherence study found that patients who stopped were much more likely to have used treatment for less than three months, often because they had not yet seen improvement. A survey from the University of Michigan similarly identified regular application and the need for continuous use among patients' main concerns.
This creates a difficult cycle: minoxidil requires consistent use for months to show meaningful results, but the daily effort and slow response make patients less likely to continue.
From my perspective, a prescription that sits in a bathroom cabinet isn't a successful treatment. If a patient cannot realistically maintain topical applications, a once-daily tablet may be a better practical choice, assuming it is medically appropriate.
Low-dose oral minoxidil offers a practical alternative. Instead of placing a product on the scalp, a patient takes a tablet, usually once daily, under medical supervision.
That removes the cosmetic inconvenience of a scalp product and makes the routine much simpler. For someone who already takes a daily medication, adding a tablet may be easier than building an entirely separate hair-care routine around a topical solution.
Ease of use matters because hair-loss treatment is usually long term. It is entirely possible for two treatments to have similar biological effectiveness in a clinical study, yet for one to be more useful to an individual patient because they will actually stick with it.
The trade-off is systemic exposure. Oral minoxidil circulates throughout the body, which explains both its potential benefit and some of its side effects. Convenience does not make it the safer choice for everyone.
There is an important Canadian distinction: oral minoxidil is a prescription medication approved for severe hypertension, not for hair loss. Prescribing it for alopecia is an off-label use. Off-label prescribing is a legitimate part of medical practice, but it requires an informed discussion of the evidence, risks and alternatives.
The doses studied for hair loss are much lower than the historical doses used to treat severe hypertension. Lower doses generally reduce the likelihood of systemic effects, but they do not eliminate those risks.
This is where the recent research is especially helpful.
A 2024 randomized clinical trial involving 90 men compared oral minoxidil, 5 mg daily, with 5% topical minoxidil used twice daily. After 24 weeks, oral minoxidil was not superior on the trial's main hair-density measurements. A photographic assessment suggested a possible advantage at the crown, but the overall results did not establish that oral treatment was better.
A meta-analysis of four randomized trials involving 279 patients reached a similar conclusion. Across the studies, researchers did not identify a significant difference in hair density or hair-shaft diameter between oral and topical treatment. Unwanted hair growth elsewhere on the body was more frequent with oral minoxidil.
More recently, a randomized study published in October 2026 compared low-dose oral minoxidil with topical treatment in men and women with pattern hair loss. After six months, improvement was seen in approximately 67% of patients in the oral group and 73% in the topical group. That difference was not statistically significant. Patients taking oral minoxidil reported somewhat greater satisfaction, but the study was not designed to prove that the treatments were equivalent.
Those are encouraging findings for oral minoxidil, but they aren't evidence that the tablet is a stronger version of the scalp treatment.
The more interesting advantage may happen outside a controlled trial. If a patient applies topical minoxidil inconsistently because of residue, styling difficulties or frustration with the routine, they may receive less benefit than the medication could otherwise provide. Switching to an oral formulation may improve actual use, even if the medications have similar efficacy when taken as directed. That practical benefit is plausible and supported by small adherence studies, but it hasn't been established in a large, long-term randomized comparison.
My interpretation is that both options can be useful. If topical minoxidil is working well and causing no problems, there isn't an automatic reason to switch simply because oral minoxidil is receiving more attention. But if someone keeps stopping the topical treatment, convenience becomes a legitimate clinical consideration.
Minoxidil can be useful for both men and women, although the diagnosis still matters. A widening part, diffuse thinning around menopause and sudden shedding after an illness are not necessarily the same condition.
A smaller randomized trial in women with female-pattern hair loss compared 1 mg oral minoxidil daily with topical 5% minoxidil. Both groups improved, and the difference between treatments was not statistically significant.
Oral minoxidil may be worth discussing when a woman has difficulty using topical treatment consistently or cannot tolerate the scalp formulation. But the decision should also account for blood pressure, other medications, pregnancy plans and the possibility of unwanted facial hair growth.
Pregnant or breastfeeding patients, and those planning pregnancy, should not use oral minoxidil for cosmetic hair loss. Treatment choices during these periods require individualized medical advice.
This is the part of the discussion I never want patients to overlook. A tablet may be more convenient, but it also exposes the entire body to a medication originally developed to affect blood pressure.
The most common side effect is hypertrichosis: increased hair growth in places other than the scalp. That may include the cheeks, upper lip, arms or other areas.
In a large retrospective study of 1,404 patients using low-dose oral minoxidil, approximately 15% reported unwanted hair growth. In the 2024 randomized trial of men taking 5 mg daily, the proportion was considerably higher. The frequency varies with dose, the population studied and how carefully the effect is assessed.
For some patients, this is a minor inconvenience. For others, particularly those concerned about facial hair, it may be a reason to choose topical treatment instead.
Oral minoxidil can cause lightheadedness, changes in blood pressure, fluid retention, ankle or facial swelling, headaches and an increased heart rate or palpitations.
The large 1,404-patient study reported lightheadedness in 1.7%, fluid retention in 1.3% and tachycardia in 0.9% of patients. Those numbers are reassuring, but the study was retrospective and cannot rule out uncommon or delayed complications.
Rare serious cardiac complications, including pericardial effusion—fluid around the heart—have been reported with systemic minoxidil. The exact risk at the low doses used for hair loss is not well established. Someone with heart disease, an arrhythmia, kidney disease, low blood pressure, significant swelling or interacting medications may require additional evaluation or may not be an appropriate candidate.
Before prescribing oral treatment, I believe the discussion has to include medical history, current medications, blood pressure and any need for additional monitoring. Symptoms such as chest pain, significant shortness of breath, fainting, rapid heartbeat or new substantial swelling warrant prompt medical assessment.
It can, whether applied to the scalp or taken orally.
Some patients notice increased shedding in the first several weeks after starting treatment. Minoxidil can shift follicles through the hair cycle, causing resting hairs to shed as new growth begins. This is sometimes called the "dread shed," and it can be unsettling for someone who is already worried about losing hair.
When this occurs, it is often temporary. But not every episode of increased shedding is caused by minoxidil, and persistent or severe shedding deserves reassessment rather than automatic reassurance.
Hair improvement is gradual. I generally encourage patients to think in months, not weeks. Visible changes may begin after several months, and a fair assessment often requires six to twelve months of consistent treatment, with standardized photographs where possible.
Minoxidil is a maintenance treatment, not a cure for genetic hair loss.
If it has helped preserve or improve hair growth, those benefits generally diminish after treatment is stopped. Over the following months, the hair may move back towards the pattern it would have followed without the medication.
That doesn't mean minoxidil caused the underlying hair loss. It means the medication was helping support follicles that remain vulnerable to the original condition.
Before starting, patients should understand that successful treatment usually requires ongoing use.
No. Not routinely.
Combining them may be considered in selected circumstances, but there is limited high-quality evidence that using both consistently produces a meaningful advantage over an appropriately chosen single formulation. Combining treatments may also increase exposure and the burden of side effects.
I would rather make sure the diagnosis is correct, choose a formulation the patient can tolerate and monitor the response than automatically prescribe more medication.
At FORM Face + Body, the first step is understanding why someone is losing hair. A receding hairline, widening part and sudden diffuse shedding can have very different causes.
I use clinical assessment, trichoscopy and standardized imaging to examine hair density and miniaturization. Depending on the findings, we may need to consider nutritional issues, medical conditions, medications, hormonal changes or inflammatory scalp disease.
For androgenetic alopecia, minoxidil can help maintain or improve existing hair. Other treatments, including finasteride or dutasteride when appropriate, work differently by addressing the DHT pathway. Selected patients may also consider additional scalp treatments or, once hair loss is suitably stabilized, hair transplantation.
A transplant moves follicles; it doesn't stop ongoing loss in the hair that remains. That is one reason medical treatment can remain important before and after surgery.
There is no single pill, foam or device that replaces a thoughtful diagnosis and long-term plan.
Not necessarily. Randomized studies have found improvement with both oral and topical minoxidil, without consistent evidence that oral treatment produces better hair density. Oral treatment may be more convenient for some patients, but it also has more potential for body-wide side effects.
Often, it's adherence. Topical minoxidil can leave the hair feeling greasy, stiff or coated, make styling more difficult and become inconvenient to apply every day. A tablet is simpler. Small studies suggest patients using oral minoxidil may miss fewer treatment days, but that practical advantage has to be weighed against the possibility of systemic side effects.
There is not convincing evidence that oral treatment reliably works faster than topical treatment. Both require patience, and meaningful changes usually take months.
Yes. It was originally developed as a blood-pressure medication. Although hair-loss doses are lower, lightheadedness, changes in blood pressure, swelling and a faster heart rate can occur. Medical screening matters.
It can. Unwanted facial or body hair growth is one of the most common adverse effects and is reported more often with oral than topical treatment.
No. They do different things. Minoxidil helps support hair growth; finasteride reduces the conversion of testosterone to DHT. For some patients with androgenetic alopecia, both pathways are relevant. The appropriate plan depends on diagnosis, goals, contraindications and tolerance for potential adverse effects.
It may be considered to help support remaining native hair in an appropriate patient. It is not a guarantee that every transplanted graft will survive, and it does not replace surgical planning or follow-up.
Oral minoxidil may seem like a new development in hair restoration, but its story began decades ago with a medication for high blood pressure. What's changed is our interest in using much lower doses to help selected patients with hair loss.
I'm encouraged that we have another useful option. I'm also cautious about calling it a breakthrough simply because it comes in a tablet.
For many people, the difference isn't potency. It's practicality. Topical minoxidil can alter the way the hair feels, interfere with styling and become a daily nuisance. Patients stop applying it, and a treatment they might have benefited from is abandoned. Oral minoxidil is easier to take, and that may be the main reason to choose it.
Topical minoxidil remains a well-established treatment, and someone using it consistently with good results does not automatically need to switch. Oral minoxidil can be an effective alternative when the topical routine is getting in the way of long-term treatment. The best available comparisons have not shown that oral treatment is consistently superior, and the possibility of systemic side effects deserves respect.
If you're experiencing hair loss and are wondering which option is right for you, I invite you to come in for a hair-restoration assessment at FORM Face + Body in Toronto. We'll determine what's causing the thinning, review the treatments that make sense for your health and goals, and build a plan focused on protecting the hair you have for the long term.
written by
Dr. Michael Brandt is a Royal College-certified Otolaryngology – Head and Neck Surgeon specializing in facial plastic and reconstructive surgery. He is fellowship-trained in facial plastic surgery and serves as an Assistant Professor at the University of Toronto, where he contributes to surgical education and research.
